

References: Benefits of Jardiance in HF Treatment

1. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication's Supplementary Appendix.)
2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med.* 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR- Preserved results and the publication's Supplementary Appendix.)
3. JARDIANCE® [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; [December 2023].
4. Butler J, Anker SD, Filippatos G, et al; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J.* 2021;42(13):1203-1212. doi:10.1093/eurheartj/ehaa1007
5. Butler J, Filippatos G, Siddiqi J, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. *Circulation.* 2022;145(3):184-193. doi:10.1161/CIRCULATIONAHA.121.057812